Summary: Researchers have uncovered the molecular mechanisms behind cognitive deficits and brain fog associated with chemotherapy, and identified a current FDA-approved drug for multiple sclerosis that can help reduce chemotherapy-induced cognitive impairments.
Source: St Louis University
Though chemotherapy can be lifesaving, the cancer treatment often leaves patients suffering from debilitating side effects, including cognitive impairments in processing speed, memory, executive function and attention. Dubbed chemo brain, these lingering symptoms can dramatically impact patients quality of life long after they have completed their cancer treatments.
Currently, there are no FDA-approved drugs to mitigate these deficits. In breakthrough findings, renowned Saint Louis University pain researcher Daniela Salvemini, Ph.D., and her team have uncovered some of the molecular events that happen whenchemotherapydrugs cause these deficits.
More promising still, theyve found that an already-approved FDA drug designed to treat multiple sclerosis also appears to work to reduce chemotherapy-related cognitive impairment (CRCI).
A growing need
The National Cancer Institute (NCI) expects cancer survivorship to reach 21. 7 million by 2029. As survivorship advances, the need to address chemotherapys severe, long-lasting neurotoxic side effects is increasing.
CRCI is a major neurotoxic side effect of chemotherapy, affecting more than 50% of patients treated with widely usedchemotherapy drugs, including taxanes like Paclitaxel and platinum-based agents like Cisplatin. These drugs are widely used as part of standard treatment for numerous cancers, including head and neck, testicular, colon, breast, ovarian and non-small cell lung cancers.
When assessed by neuropsychological tests, up to 75% percent of patients treated with chemotherapy for cancers outside the nervous system reported cognitive deficits.
Salvemini, who is the William Beaumont professor of pharmacology and physiology and Chair of the department at Saint Louis University, says CRCI profoundly affects patient quality of life.
Our current understanding of the mechanisms underlying CRCI and their impact on cognition is limited due to the multifactorial origins of CRCI, said Salvemini, who is also director of the Henry and Amelia Nasrallah Center for Neuroscience at SLU and a fellow of the Saint Louis Academy of Science.
A better understanding of these mechanisms is essential for developing new therapies and improving survivors quality of life.
New findings
In her most recent paper, Sphingosine-1-Phosphate Receptor 1 Activation in the Central Nervous System Drives Cisplatin-Induced Cognitive Impairments, published Sept. 1, 2022, in theJournal of Clinical Investigation, Salvemini and her team present the first evidence that chemotherapy alters an important cellular pathway called sphingolipid metabolism in critical areas of the brain linked to cognitive function.
Salvemini notes that in the central nervous system, Cisplatin increases levels of the potent signaling molecule sphingosine-1-phosphate (S1P), which contributes to the development of CRCI through activation of S1P receptor subtype 1 (S1PR1) on astrocytes and S1PR1-driven mitochondrial dysfunction and neuroinflammatory processes. Mechanistically, she says the team revealed that cisplatin-induced S1P formation is mediated by the toll-like receptor 4.
Their findings bridge the gaps in understanding themolecular mechanismsunderlying CRCI and identify a novel target for therapeutic intervention with functional S1PR1 antagonists. Importantly, S1PR1 antagonists do not interfere with the efficacy of chemotherapy as they and others have shown in previous work and can also block tumor cell growth, inflammation and metastasis.
Our findings are fascinating since two functional S1PR1 antagonists are already FDA-approved for treating multiple sclerosis, Salvemini said. Repurposing these drugs to prevent CRCI would be a groundbreaking shift towards enhancing patient quality of life in cancer treatment.
In previous studies, Salvemini pioneered research on a treatment for neuropathic pain that could provide the first alternative to ineffective steroids and addictive opioids.
Work from Salveminis lab established that altered S1PR1 signaling in the centralnervous systemin response to chemotherapy also contributes to chemotherapy-induced neuropathic pain, another central neurotoxicity ofcancer treatment.
This work fueled two ongoing NCIclinical trialsto test the potential use of Gilenya, a drug approved to treat multiple sclerosis, to preventneuropathic painin patients with breast cancer treated with Paclitaxel.
Our work is very translational, Salvemini said. We try to understand the mechanisms at themolecular level, identify the targets, work with our chemists to make new drugs to target that specific pathway, test it, and then take the necessary steps to move along this compound until it is ready to be studied in a clinical trial.
Author: Press OfficeSource: St Louis UniversityContact: Press Office St Louis UniversityImage: The image is in the public domain
Original Research: Open access.Sphingosine-1-phosphate receptor 1 activation in the central nervous system drives cisplatin-induced cognitive impairment by Silvia Squillace et al. Journal of Clinical Investigation
Abstract
Sphingosine-1-phosphate receptor 1 activation in the central nervous system drives cisplatin-induced cognitive impairment
Cancer-related cognitive impairment (CRCI) is a major neurotoxicity affecting more than 50% of cancer survivors. The underpinning mechanisms are mostly unknown, and there are no FDA-approved interventions.
Sphingolipidomic analysis of mouse prefrontal cortex and hippocampus, key sites of cognitive function, revealed that cisplatin increased levels of the potent signaling molecule sphingosine-1-phosphate (S1P) and led to cognitive impairment. At the biochemical level, S1P induced mitochondrial dysfunction, activation of NOD-, LRR-, and pyrin domaincontaining protein 3 inflammasomes, and increased IL-1 formation.
These events were attenuated by systemic administration of the functional S1P receptor 1 (S1PR1) antagonist FTY720, which also attenuated cognitive impairment without adversely affecting locomotor activity. Similar attenuation was observed with ozanimod, another FDA-approved functional S1PR1 antagonist.
Mice with astrocyte-specific deletion ofS1pr1lost their ability to respond to FTY720, implicating involvement of astrocytic S1PR1. Remarkably, our pharmacological and genetic approaches, coupled with computational modeling studies, revealed that cisplatin increased S1P production by activating TLR4.
Collectively, our results identify the molecular mechanisms engaged by the S1P/S1PR1 axis in CRCI and establish S1PR1 antagonism as an approach to target CRCI with therapeutics that have fast-track clinical application.
Original post:
Unlocking the Mystery of Chemo Brain - Neuroscience News
- Marcus Neuroscience Institute to Host Brain and Spine Symposium - South Florida Hospital News - March 30th, 2025 [March 30th, 2025]
- Elon University to launch neuroscience major in fall 2025 - Today at Elon - March 30th, 2025 [March 30th, 2025]
- The brains stalwart sentinels express an unexpected gene - The Transmitter: Neuroscience News and Perspectives - March 30th, 2025 [March 30th, 2025]
- Video catches microglia in the act of synaptic pruning - The Transmitter: Neuroscience News and Perspectives - March 30th, 2025 [March 30th, 2025]
- Null and Noteworthy: Reexamining registered reports - The Transmitter: Neuroscience News and Perspectives - March 30th, 2025 [March 30th, 2025]
- Accepting the bitter lesson and embracing the brains complexity - The Transmitter: Neuroscience News and Perspectives - March 30th, 2025 [March 30th, 2025]
- NIH neurodevelopmental assessment system now available as iPad app - The Transmitter: Neuroscience News and Perspectives - March 30th, 2025 [March 30th, 2025]
- Stronger Bonds Before Birth Shape Healthier Mother-Child Futures - Neuroscience News - March 30th, 2025 [March 30th, 2025]
- How Emotionally Intelligent People Learn to Control Their Inner Voice, Backed by Neuroscience - Inc. - March 30th, 2025 [March 30th, 2025]
- Gabriele Scheler reflects on the interplay between language, thought and AI - The Transmitter: Neuroscience News and Perspectives - March 30th, 2025 [March 30th, 2025]
- Worlds first crowd-sourced neuroscience study aims to understand how our brains predict the future - EurekAlert - March 15th, 2025 [March 15th, 2025]
- Rewriting Neuroscience: Possible Foundations of Human Intelligence Observed for the First Time - SciTechDaily - March 15th, 2025 [March 15th, 2025]
- Calculating neurosciences carbon cost: Q&A with Stefan Pulver and William Smith - The Transmitter: Neuroscience News and Perspectives - March 15th, 2025 [March 15th, 2025]
- The future of neuroscience research at U.S. minority-serving institutions is in danger - The Transmitter: Neuroscience News and Perspectives - March 15th, 2025 [March 15th, 2025]
- Dopamine and social media: Why you cant stop scrolling, according to neuroscience - PsyPost - March 15th, 2025 [March 15th, 2025]
- Neuroscience Discovered a Clever Trick for Squeezing More Joy Out of Everyday Pleasures - Inc. - March 15th, 2025 [March 15th, 2025]
- The limits of neuroscience - The Transmitter: Neuroscience News and Perspectives - March 15th, 2025 [March 15th, 2025]
- BPOM Explains The Benefits Of Fasting From The Health And Neuroscience Side - VOI English - March 15th, 2025 [March 15th, 2025]
- How tiny tardigrades could help tackle systems neuroscience questions - The Transmitter: Neuroscience News and Perspectives - March 15th, 2025 [March 15th, 2025]
- Alison Preston explains how our brains form mental frameworks for interpreting the world - The Transmitter: Neuroscience News and Perspectives - March 15th, 2025 [March 15th, 2025]
- The Mystical Mind Meets Neuroscience: Seeking the Roots of Consciousness - Next Big Idea Club Magazine - March 15th, 2025 [March 15th, 2025]
- Myosin Therapeutics Closes Second Seed Round to Advance Clinical Trials for Innovative Cancer and Neuroscience Therapies - PR Newswire - March 5th, 2025 [March 5th, 2025]
- Neuroscience Ph.D. programs adjust admissions in response to U.S. funding uncertainty - The Transmitter: Neuroscience News and Perspectives - March 5th, 2025 [March 5th, 2025]
- New tools help make neuroimaging accessible to more researchers - The Transmitter: Neuroscience News and Perspectives - March 5th, 2025 [March 5th, 2025]
- Future Thinking Training Reduces Impulsivity - Neuroscience News - March 5th, 2025 [March 5th, 2025]
- Null and Noteworthy, relaunched: Probing a schizophrenia biomarker - The Transmitter: Neuroscience News and Perspectives - March 5th, 2025 [March 5th, 2025]
- How to communicate the value of curiosity-driven research - The Transmitter: Neuroscience News and Perspectives - March 5th, 2025 [March 5th, 2025]
- Cognitive neuroscience approach to explore the impact of wind turbine noise on various mental functions - Nature.com - March 5th, 2025 [March 5th, 2025]
- Football on the Brain: Helping coaches embed neuroscience knowledge - Training Ground Guru - March 5th, 2025 [March 5th, 2025]
- Taking Control: Using Neuroscience to Build Better Lives - theLoop - March 5th, 2025 [March 5th, 2025]
- Creating a pipeline of talent to feed the growth of Neuroscience: Lessons from Ghana - Myjoyonline - March 5th, 2025 [March 5th, 2025]
- Exclusive: NIH appears to archive policy requiring female animals in studies - The Transmitter: Neuroscience News and Perspectives - February 25th, 2025 [February 25th, 2025]
- Roll On Down The Highway 2025 Tour coming to Neuroscience Group Field - WeAreGreenBay.com - February 25th, 2025 [February 25th, 2025]
- STEM organizations host Neuroscience Outreach Fair for local K-12 students - University of Virginia The Cavalier Daily - February 25th, 2025 [February 25th, 2025]
- Adapt or die: Safeguarding the future of diversity and inclusion funding in neuroscience - The Transmitter: Neuroscience News and Perspectives - February 25th, 2025 [February 25th, 2025]
- The last two-author neuroscience paper? - The Transmitter: Neuroscience News and Perspectives - February 25th, 2025 [February 25th, 2025]
- Gate Neurosciences Strengthens Focus on the Synapse as a Therapeutic Target with Acquisition of Boost Neuroscience - Business Wire - February 25th, 2025 [February 25th, 2025]
- Why Firefly Neuroscience, Inc. (AIFF) Is Soaring This Year So Far - Yahoo Finance - February 25th, 2025 [February 25th, 2025]
- Breaking the barrier between theorists and experimentalists - The Transmitter: Neuroscience News and Perspectives - February 25th, 2025 [February 25th, 2025]
- Preserving Brain Health and Advancing Neuroscience - University of Miami - February 25th, 2025 [February 25th, 2025]
- Science must step away from nationally managed infrastructure - The Transmitter: Neuroscience News and Perspectives - February 25th, 2025 [February 25th, 2025]
- Repurposed Blood Pressure Drug May Treat ADHD - Neuroscience News - February 25th, 2025 [February 25th, 2025]
- How to teach students about science funding - The Transmitter: Neuroscience News and Perspectives - February 25th, 2025 [February 25th, 2025]
- Reflecting on 2024: Advancing Neuroscience Research to Improve Neurological Health - National Institute of Neurological Disorders and Stroke - February 25th, 2025 [February 25th, 2025]
- Brains Hidden Circuitry for Risk and Reward Uncovered - Neuroscience News - February 25th, 2025 [February 25th, 2025]
- Why We Keep Exploring Even After Learning the Best Strategy - Neuroscience News - February 25th, 2025 [February 25th, 2025]
- Unlocking Cellular Youth: The Protein That Reverses Aging - Neuroscience News - February 25th, 2025 [February 25th, 2025]
- This paper changed my Life: Bill Newsome reflects on a quadrilogy of classic visual perception studies - The Transmitter: Neuroscience News and... - February 25th, 2025 [February 25th, 2025]
- Roundup: The false association between vaccines and autism - The Transmitter: Neuroscience News and Perspectives - February 3rd, 2025 [February 3rd, 2025]
- Static pay, shrinking prospects fuel neuroscience postdoc decline - The Transmitter: Neuroscience News and Perspectives - February 3rd, 2025 [February 3rd, 2025]
- Stimulating the brain with Damien Fair - The Transmitter: Neuroscience News and Perspectives - February 3rd, 2025 [February 3rd, 2025]
- Unhealthy Diet Linked to Faster Biological Aging in Young Adults - Neuroscience News - February 3rd, 2025 [February 3rd, 2025]
- Bob Smittcamp Family Neuroscience Institute coming to Fresno in 2026 - ABC30 News - February 3rd, 2025 [February 3rd, 2025]
- Norton Neuroscience Institute selected to pilot national Brain Health Navigator program - Norton Healthcare - February 3rd, 2025 [February 3rd, 2025]
- Coding bonus: Bats hippocampal cells log spatial, social cues - The Transmitter: Neuroscience News and Perspectives - February 3rd, 2025 [February 3rd, 2025]
- ADHD and brainwaves: How neuroscience is changing the way we diagnose the condition - PsyPost - February 3rd, 2025 [February 3rd, 2025]
- David Robbe challenges conventional notions of time and memory - The Transmitter: Neuroscience News and Perspectives - February 3rd, 2025 [February 3rd, 2025]
- How the Brain Processes Space and Time - Neuroscience News - February 3rd, 2025 [February 3rd, 2025]
- Using neuroscience to help establish healthier habits | Opinion - South Bend Tribune - February 3rd, 2025 [February 3rd, 2025]
- Solvonis chairman on heavy-hitting M&A in neuroscience sector - ICYMI - Proactive Investors UK - February 3rd, 2025 [February 3rd, 2025]
- New neuroscience research sheds light on distinct patterns of learning and generalization in autistic adults - PsyPost - January 23rd, 2025 [January 23rd, 2025]
- Neuroscientists need to do better at explaining basic mental health research - The Transmitter: Neuroscience News and Perspectives - January 23rd, 2025 [January 23rd, 2025]
- How Severance shows the possibilities of cognitive neuroscience - Fast Company - January 23rd, 2025 [January 23rd, 2025]
- AdventHealth Welcomes New Leadership In Heart and Vascular Services, Neuroscience and Orthopedics - Northwest Georgia News - January 23rd, 2025 [January 23rd, 2025]
- School of Neuroscience and Language Sciences Program recognized with University Exemplary Department or Program Award - Virginia Tech - January 23rd, 2025 [January 23rd, 2025]
- Early Exposure to Violent Media Linked to Teen Antisocial Behavior - Neuroscience News - January 23rd, 2025 [January 23rd, 2025]
- The Real Cognitive Neuroscience Behind Severance - WIRED - January 23rd, 2025 [January 23rd, 2025]
- The 15 most popular psychology and neuroscience studies in 2024 - PsyPost - January 1st, 2025 [January 1st, 2025]
- The 'lizard brain' lie: How neuroscience demolished the greatest mind myth - BBC Science Focus - January 1st, 2025 [January 1st, 2025]
- Revolutionizing Brain Diagnostics with Light and AI - Neuroscience News - January 1st, 2025 [January 1st, 2025]
- How Early Experiences Shape Genes, Brain Health, and Resilience - Neuroscience News - January 1st, 2025 [January 1st, 2025]
- A nation exhausted: The neuroscience of why Americans are tuning out political news - Indiana Capital Chronicle - January 1st, 2025 [January 1st, 2025]
- Lithium Restores Brain Function and Behavior in Autism - Neuroscience News - January 1st, 2025 [January 1st, 2025]
- Partners in Diversity presents the science of belonging: exploring the neuroscience of inclusion - Here is Oregon - January 1st, 2025 [January 1st, 2025]
- Classical vs. Operant Conditioning: The Brain's Memory Tug-of-War - Neuroscience News - January 1st, 2025 [January 1st, 2025]
- The Personality Gap Between Singles and the Partnered - Neuroscience News - January 1st, 2025 [January 1st, 2025]
- The Neuroscience Behind Vermeers Girl and Its Hypnotic Power - ZME Science - January 1st, 2025 [January 1st, 2025]
- Serotonin, GABA, and Dopamine Drive Hunger and Feeding - Neuroscience News - December 23rd, 2024 [December 23rd, 2024]
- A nation exhausted: The neuroscience of why Americans are tuning out politics - The Conversation - December 23rd, 2024 [December 23rd, 2024]
- UNO Goalie and Neuroscience Grad Shines in Her Athletic and Academic Aspirations - University of Nebraska Omaha - December 23rd, 2024 [December 23rd, 2024]